Login to Your Account

Discovery Labs' RDS Therapy Hits Main Phase III Endpoints

By Randall Osborne

Wednesday, November 26, 2003
Discovery Laboratories Inc. reaped more good news with Surfaxin, which met statistical significance in the co-primary endpoints of a pivotal Phase III trial in premature infants afflicted with respiratory distress syndrome. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription